Ashwa-stress
Food supplement declared in France
Ashwa-stress is a food supplement declared in France. Status: retrait du marché annoncé pour le 26 May 2029. None of the rules we check flags an issue with its declared composition; vitamin and mineral doses are not published by Compl'Alim and are therefore not checked.
- Brand
- not provided
- Food business operator placing the product on the market
- LAB. O2&VIE SAS
- Status
- Retrait du marché annoncé pour le 26 May 2029
- Form
- Gélule
- Daily dose
- Prendre 2 gélules par jours
- Not recommended for (according to the manufacturer)
- Adolescents (moins de 18 ans), Femmes allaitantes, Femmes enceintes, Problèmes cardiaques, Problèmes de foie, Sous antidépresseurs
Declaration 361363, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.
Regulatory points
- Information
Retrait du marché annoncé pour le 26 May 2029, according to Compl'Alim.
Source: Compl'Alim, food supplement declarations (France).
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Withania somnifera (L.) Dunal | Racine | Extrait sec hydroalcoolique | 500 mg |
Substances
| Name | Per day |
|---|---|
| acide lipoïque | 99 mg |
| tyrosine | 39 mg |
Vitamins and minerals
Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).
| Declared form | Nutrient | EFSA limit, adults | Maximum dose in France |
|---|---|---|---|
| Acide L-ascorbique | Vitamine C | pas de limite (données insuffisantes) | 180 mg |
Additives
E414, E464
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Label warnings
Déconseillé chez la femme enceinte ou allaitante, la population de moins de 18 ans, les personnes atteintes de troubles endocriniens (particulièrement les dysthyroïdies et l’hyperandrogénie), les personnes atteintes de troubles hépatiques ou cardiaques, les personnes suivant un traitement ayant une action dépressive du système nerveux central et aux personnes diabétiques.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Other declarations with the same name
In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.
- Ashwa-stress LAB. O2&VIE SAS, declared in 2026 : same declared composition